Join us

Engage with us in a change of paradigm

  • Arrow logo brenus pharma

    Efficient technology

    Anticipates risks of tumor escape by targeting over 250 cancer-related antigens driven by relapse mechanism.

    Answers huge unmet need in solid tumors : Platform strategy, combining impactful technologies, with standardized steps for a quicker generation of immunotherapy for solid tumors.

  • Arrow logo brenus pharma

    Derisked approach

    2nd generation of innovative cancer vaccine strategy : previous haptenized approaches show significative historical clinical DATA (Glioblastoma + Melanoma).

    Preclinical package endoresed with FDA Pre-IND passed.

    GMP manufacturing ready.

    Top international scientific leader on board & experienced governance in Healthtech industries.

  • Arrow logo brenus pharma

    Limitless potential

    IP by design-platform strategy ; 22 patent granted.

    Tailored first-in-class drugs design.

    Dynamic immuno-oncology market with mRNA and Personalized Cancer Vaccine.

    Ensuring treatment's availability to a wide population of patient in therapeutic issue.

Key milestones validated

  • Preclinical & Regulatory

    • mCRC preclinical package for the lead candidate, STC-1010, finalized (in-vivo, ex-vivo) endorsed by FDA & FAMHP (EMA).
    • Published in major congress : SITC, AACR, ASCO
  • Manufacturing

    • Product - GLP, Drugs subsances - GMP
    • Gap Analysis
    • Pre scale-up & Tech transfer - GMP, experienced CDMO
  • First-In-Human

    • Phase I/II 1L mCRC study synopsis validated (US,BEL,FR)
  • IP

    • STC platform design - Granted in Key countries
    • STC-1010 Product - Published
  • Team

    • Highly skilled executives and operationals & internationally renowed KOLs on board
Cells Brenus pharma steps

Competitive advantages

STC Technology overpassing current challenges in the field of immuno oncology

Cells Brenus pharma steps

Brenus’ STC immunotherapy is administered in first line

In combination with standard of care

  • Possible synergy with immunotherapies : They are not necessarily competitors
  • No other allogeneic vaccine identified to date

With the support of

With the support of

Our awards

  • MATWIN 2021 award
  • Finalist 2022
    Boston 2022
    "Best startup in the Pharmaceutical or Biotech industry"
  • ENRICH IN USA 2022 award